Combined phenotype/genotype datasets. These are (with some good reason) very difficult for anyone outside the medical-research establishment to get access to, but the net result is that it creates market barriers supporting the existing big players.
These are quite difficult to get (and very expensive to produce) even inside the medical-research establishment. Which big players are you referring to?